 Bristol Myers Squibb Co. said Thursday it had a net loss of 10.027 billion, or 4.45 a share, in the fourth quarter, wider than the loss of 1.056 billion, or 55 cents a share, posted in the year-earlier period, weighed down by charges relating to the MyoKardia asset acquisition, the purchase of Celgene, contingent value rights air value adjustments, equity investment gains, intangible assets impairment charges and other acquisition and integration expenses. Excluding those charges, the company had per-share earnings of 1.46, ahead of the 1.42 FactSet consensus. 